ATE453389T1 - Bestimmte pharmazeutisch wertvolle substituierte aminoalkyl-heterocyclen - Google Patents

Bestimmte pharmazeutisch wertvolle substituierte aminoalkyl-heterocyclen

Info

Publication number
ATE453389T1
ATE453389T1 AT03719457T AT03719457T ATE453389T1 AT E453389 T1 ATE453389 T1 AT E453389T1 AT 03719457 T AT03719457 T AT 03719457T AT 03719457 T AT03719457 T AT 03719457T AT E453389 T1 ATE453389 T1 AT E453389T1
Authority
AT
Austria
Prior art keywords
substituted aminoalkyl
certain pharmaceutically
pharmaceutically valuable
heterocycles
valuable substituted
Prior art date
Application number
AT03719457T
Other languages
English (en)
Inventor
Scott Thompson
James Frazee
Lara Kallander
Chum Ma
Joseph Marino
Michael Neeb
Ajita Bhat
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Application granted granted Critical
Publication of ATE453389T1 publication Critical patent/ATE453389T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Furan Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT03719457T 2002-03-27 2003-03-26 Bestimmte pharmazeutisch wertvolle substituierte aminoalkyl-heterocyclen ATE453389T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36841502P 2002-03-27 2002-03-27
PCT/US2003/009039 WO2003082192A2 (en) 2002-03-27 2003-03-26 Certain pharmaceutically useful substituted aminoalkyl heterocycles

Publications (1)

Publication Number Publication Date
ATE453389T1 true ATE453389T1 (de) 2010-01-15

Family

ID=28675483

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03719457T ATE453389T1 (de) 2002-03-27 2003-03-26 Bestimmte pharmazeutisch wertvolle substituierte aminoalkyl-heterocyclen

Country Status (8)

Country Link
US (1) US7323494B2 (de)
EP (1) EP1490047B1 (de)
JP (1) JP2005521705A (de)
AT (1) ATE453389T1 (de)
AU (1) AU2003223340A1 (de)
DE (1) DE60330758D1 (de)
ES (1) ES2337037T3 (de)
WO (1) WO2003082192A2 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002024632A2 (en) * 2000-09-18 2002-03-28 Glaxo Group Limited Substituted aminopropoxyaryl derivatives useful as agonists for lxr
AU2003220558A1 (en) 2002-03-27 2004-06-03 Smithkline Beecham Corporation Amide compounds and methods of using the same
AU2003220521A1 (en) * 2002-03-27 2003-10-13 Smithkline Beecham Corporation Methods of treatment with lxr modulators
US7365085B2 (en) 2002-03-27 2008-04-29 Smithkline Beecham Corporation Compounds and methods
JP2005521721A (ja) 2002-03-27 2005-07-21 スミスクライン・ビーチャム・コーポレイション 酸およびエステル化合物ならびにその使用方法
MXPA05004811A (es) * 2002-11-06 2005-07-22 Schering Corp Inhibidores de absorcion de colesterol para el tratamiento de trastornos autoinmunes.
FR2869904B1 (fr) 2004-05-07 2006-07-28 Fournier S A Sa Lab Modulateurs des recepteurs lxr
IL166149A0 (en) * 2005-01-05 2006-01-15 Hadasit Med Res Service Use of ezetimibe and amiodarone in protection against beta-amyloid neurotoxicity
KR20090086084A (ko) 2006-11-30 2009-08-10 코와 가부시키가이샤 치환 카르비놀 화합물
EP2248811B1 (de) 2008-02-29 2012-11-14 Kowa Company, Ltd. 2-oxochromen-derivat
EP2264029A4 (de) 2008-03-31 2011-08-24 Kowa Co 1,3-dihydroisobenzofuran-derivat
EP2272843A4 (de) 2008-04-30 2011-07-20 Kowa Co Chinolinverbindung
US8153634B2 (en) 2008-05-29 2012-04-10 Kowa Company, Ltd. Carbinol derivatives having cyclic linker
JP5774984B2 (ja) 2009-04-29 2015-09-09 興和株式会社 ヘテロ環リンカーを有するカルビノール化合物
US20130274212A1 (en) 2010-09-07 2013-10-17 Snu R&Db Foundation Sesterterpene Compounds and Use Thereof
AU2018226879B2 (en) 2017-03-03 2023-09-14 Inspirna, Inc. Formulations with improved stability

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0394440B1 (de) 1987-10-20 1994-05-11 Otsuka Pharmaceutical Co., Ltd. Phenylcarbonsäure-abkömmlinge
US20030153541A1 (en) 1997-10-31 2003-08-14 Robert Dudley Novel anticholesterol compositions and method for using same
US6316503B1 (en) 1999-03-15 2001-11-13 Tularik Inc. LXR modulators
WO2001060818A1 (en) * 2000-02-14 2001-08-23 Tularik Inc. Lxr modulators
WO2002024632A2 (en) 2000-09-18 2002-03-28 Glaxo Group Limited Substituted aminopropoxyaryl derivatives useful as agonists for lxr
EP1461028A4 (de) 2001-12-07 2007-07-25 Univ California Behandlung für altersbezogene makuladegeneration
US7470659B2 (en) 2001-12-07 2008-12-30 The Regents Of The University Of California Methods to increase reverse cholesterol transport in the retinal pigment epithelium (RPE) and Bruch's membrane (BM)
US20030229062A1 (en) 2001-12-07 2003-12-11 The Regents Of The University Of California Treatments for age-related macular degeneration (AMD)
JP2005521721A (ja) 2002-03-27 2005-07-21 スミスクライン・ビーチャム・コーポレイション 酸およびエステル化合物ならびにその使用方法
AU2003220521A1 (en) 2002-03-27 2003-10-13 Smithkline Beecham Corporation Methods of treatment with lxr modulators
AU2003220558A1 (en) 2002-03-27 2004-06-03 Smithkline Beecham Corporation Amide compounds and methods of using the same
US7365085B2 (en) 2002-03-27 2008-04-29 Smithkline Beecham Corporation Compounds and methods
US20050036992A1 (en) 2002-12-23 2005-02-17 Irm Llc Novel use of liver X receptor agonists
GB0230177D0 (en) 2002-12-24 2003-02-05 Karobio Ab LXR beta crystal
US20070099884A1 (en) 2003-06-06 2007-05-03 Erondu Ngozi E Combination therapy for the treatment of diabetes
US20060160834A1 (en) 2003-06-06 2006-07-20 Fong Tung M Combination therapy for the treatment of hypertension
US20060189693A1 (en) 2003-07-22 2006-08-24 Barone Frank C Methods of treatment with lxr agonists
JP2007500158A (ja) 2003-07-28 2007-01-11 グラクソ　グループ　リミテッド Ｌｘｒアゴニストを用いる炎症性腸疾患の治療方法
WO2005055998A1 (en) 2003-12-04 2005-06-23 Smithkline Beecham Corporation Methods of treatment with lxr agonists
JP2007516258A (ja) 2003-12-12 2007-06-21 ワイス 心臓血管の疾患治療に有用なキノリン誘導体
US20060014231A1 (en) 2004-06-24 2006-01-19 Luc Van Rompaey Methods and compositions to promote bone homeostasis
KR101266587B1 (ko) 2004-07-02 2013-05-22 상꾜 가부시키가이샤 조직 인자 생성 억제제

Also Published As

Publication number Publication date
EP1490047A4 (de) 2006-01-04
US20050165045A1 (en) 2005-07-28
EP1490047B1 (de) 2009-12-30
WO2003082192A3 (en) 2003-12-18
AU2003223340A1 (en) 2003-10-13
AU2003223340A8 (en) 2003-10-13
JP2005521705A (ja) 2005-07-21
US7323494B2 (en) 2008-01-29
DE60330758D1 (de) 2010-02-11
ES2337037T3 (es) 2010-04-20
WO2003082192A2 (en) 2003-10-09
EP1490047A2 (de) 2004-12-29

Similar Documents

Publication Publication Date Title
DE60107449D1 (de) Substituierte aminopropoxyarylderivate als lxr agonisten
WO2003082205A3 (en) Compounds and methods
ATE453389T1 (de) Bestimmte pharmazeutisch wertvolle substituierte aminoalkyl-heterocyclen
ATE297203T1 (de) Antithrombotische mitteln
DE69919397D1 (de) Thrombin-inhibitoren
NL300877I2 (nl) obeticholzuur
ATE440603T1 (de) 8-hydroxychinolinderivate
DE602004008098D1 (de) Substituierte 2h-ä1,2,4ütriazoloä4,3-aüpyrazine als gsk-3-inhibitoren
NO20020214L (no) Substituerte oksoazaheterocyklylforbindelser
TW200510441A (en) Novel compounds
CY1111481T1 (el) Υποκατεστημενα αρυλοκυκλοπροπυλακεταμιδια ως ενεργοποιητες γλυκοκινασης
BR0108893B1 (pt) composiÇço farmacÊutica contendo derivados de azetidina, composto derivado de azetidina, e, processo para a preparaÇço de compostos.
NO20032801L (no) Tiazolderivater for behandling av PPAR-relaterte forstyrrelser
DE60130771D1 (de) Substituierte heterocyclische amide
ES2243579T3 (es) Derivados de pirazolopirideno.
DE602006011752D1 (de) Als antikoagulationsmittel geeignete phenylglycinamid- und pyridylglycinamidderivate
WO2005003087A3 (en) Oxazole derivatives as antibacterial agents
EA200600694A1 (ru) Дисульфидные, сульфидные, сульфоксидные и сульфоновые производные циклических сахаров и их применение
NO20025035D0 (no) Oksadiazolderivater som har anticancer-effekter
ID24846A (id) Turunan-turunan bifenilamidina
BRPI0412636A (pt) imidazopirimidinas substituìdas para a prevenção e tratamento de cáncer
ATE308540T1 (de) Antithrombosemittel
DK1209151T3 (da) 4-substituerede piperidinderivativer
WO2003093247A3 (en) Antibacterial agents
PT1072601E (pt) Derivados de 4-arilpiperidina para o tratamento de prurido

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties